---
title: "Dongbao Bio-Tech received a warning letter from the Inner Mongolia Securities Regulatory Bureau"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/228530480.md"
description: "Dongbao Bio-Tech received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to issues in the management and use of raised funds. In the management of funds from the issuance of convertible corporate bonds in 2023, the cash management balance exceeded the authorized limit of the board of directors, and the company failed to timely fulfill the review procedures and information disclosure obligations. In addition, there were instances of untimely disclosure in the management of funds raised from the issuance of stocks in 2020. The inspection also found discrepancies between the actual investment progress of the fundraising projects and the disclosed plans"
datetime: "2025-02-17T08:46:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/228530480.md)
  - [en](https://longbridge.com/en/news/228530480.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/228530480.md)
---

# Dongbao Bio-Tech received a warning letter from the Inner Mongolia Securities Regulatory Bureau

According to the Zhitong Finance APP, Dongbao Bio-Tech (300239.SZ) announced that the company received a decision from the Inner Mongolia Securities Regulatory Bureau regarding the issuance of a warning letter. The document pointed out issues with the management and use of the company's raised funds:

First, during the cash management process using the funds raised from the issuance of convertible corporate bonds to unspecified objects in 2023, there were instances where the cash management balance exceeded the authorization limit set by the company's board of directors between January 19 and April 19, 2024, with the highest balance exceeding the authorized limit by 6 million yuan. The company did not timely fulfill its review procedures and information disclosure obligations; during the cash management process using the funds raised from the issuance of shares to specific objects in 2020, there were instances where authorized raised funds were used to purchase investment products between March 20 and April 21, 2024, with the product maturity exceeding the board's authorization and not disclosed in a timely manner.

Second, the company announced that the implementation period for the fundraising project "Comprehensive Utilization of Wastewater Resources" was until April 30, 2023. Inspections found that funds raised were still in use from April 30, 2023, to September 2024, with the full-line equipment trial run with materials scheduled to be completed by September 2024, meeting formal production conditions. However, the actual investment progress differed from the disclosed investment plan, and the company did not timely disclose the specific reasons or adjustments to the fundraising investment plan

### Related Stocks

- [300239.CN](https://longbridge.com/en/quote/300239.CN.md)

## Related News & Research

- [11:30 ETInventHelp Inventor Develops Safety System for Routine Traffic Stops (CNH-7016)](https://longbridge.com/en/news/295556245.md)
- [Herb Dock Launches Eye Scan Platform for Personalized Wellness](https://longbridge.com/en/news/295456534.md)
- [Volkswagen’s new electric era begins with reveal of ID. ERA 5X SUV](https://longbridge.com/en/news/295301574.md)
- [08:44 ETAlafair Biosciences Named to the 2026 Inc. 5000, Marking 4th Consecutive Year on the List](https://longbridge.com/en/news/295539003.md)
- [14:15 ETInventHelp Inventor Develops Modified Garden Hose Nozzle (CHK-5097)](https://longbridge.com/en/news/295436930.md)